The goal of this application is to test the hypothesis that a circulating inhibitor of vascular endothelial cell growth released by primary tumors inhibits the growth of metastases. The phenomenon of suppression of tumor growth by tumor mass is well-known, but a molecular mechanism has not been elucidated. Our preliminary data show that: (i) Primary mouse tumors inhibit growth of lung metastases; (ii) Removal of the tumor increases the number of visible metastases by 12-fold and the maximum size by 1000-fold; (iii) The suppression of metastatic growth appears to be due to inhibition of neovascularization and not to a direct inhibitory effect on the tumor cells; (iv) A specific inhibitor of endothelial proliferation has been isolated from serum and urine of tumor-bearing mice but not from mice with tumors removed. Tumor cells and other cell types are not inhibited. (v) The inhibitor has been purified from mouse urine as a 38 kD protein with an amino acid sequence homologous to an internal fragment of plasminogen, having an N-terminus at amino acid 98 and a predicted carboxy-terminus at amino acid 440, and named """"""""angiostatin."""""""" Full length plasminogen itself has no endothelial inhibitory activity. Human angiostatin co-purifies with murine angiostatin and the human cDNA has been cloned. Human angiostatin potently inhibits angiogenesis within lung metastases and growth of metastases.
Our Specific Aims are to: (1) Produce sufficient quantities of angiostatin; (2) Determine its therapeutic activity. (3) Initiate structure-activity studies of angiostatin by transfection of its cDNA and deletion mutants. (4) Identify and isolate the membrane receptor for angiostatin on vascular endothelial cells. Significance: These studies may provide: (i) A mechanism for suppression of metastasis by tumor mass; (ii) Additional direct evidence that tumor growth is angiogenesis-dependent; (iii) A novel method of discovering endogenous angiogenesis inhibitors; (iv) A possible new concept of tumor dormancy; (v) A potential new diagnostic and therapeutic approach in cancer patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Pathology B Study Section (PTHB)
Program Officer
Mohla, Suresh
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Children's Hospital Boston
United States
Zip Code
Lee, Tong-Young; Folkman, Judah; Javaherian, Kashi (2010) HSPG-binding peptide corresponding to the exon 6a-encoded domain of VEGF inhibits tumor growth by blocking angiogenesis in murine model. PLoS One 5:e9945
Lee, Tong-Young; Muschal, Stefan; Pravda, Elke A et al. (2009) Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood 114:1987-98
Panigrahy, Dipak; Kaipainen, Arja; Huang, Sui et al. (2008) PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A 105:985-90
Lee, Tong-Young; Tjin Tham Sjin, Robert M; Movahedi, Shahla et al. (2008) Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy. Clin Cancer Res 14:1487-93
Kisucka, Janka; Butterfield, Catherine E; Duda, Dan G et al. (2006) Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A 103:855-60
Almog, Nava; Henke, Vanessa; Flores, Ludmila et al. (2006) Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J 20:947-9
Tjin Tham Sjin, R M; Naspinski, J; Birsner, A E et al. (2006) Endostatin therapy reveals a U-shaped curve for antitumor activity. Cancer Gene Ther 13:619-27
Celik, Ilhan; Surucu, Oguzkan; Dietz, Carsten et al. (2005) Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 65:11044-50
Folkman, J; Ryeom, S (2005) Is oncogene addiction angiogenesis-dependent? Cold Spring Harb Symp Quant Biol 70:389-97
Satchi-Fainaro, Ronit; Mamluk, Roni; Wang, Ling et al. (2005) Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 7:251-61

Showing the most recent 10 out of 28 publications